CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases MS Subbarayan, A Joly-Amado, PC Bickford, KR Nash Pharmacology & Therapeutics 231, 107989, 2022 | 72 | 2022 |
T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson’s disease MS Subbarayan, C Hudson, LD Moss, KR Nash, PC Bickford Journal of Neuroinflammation 17, 1-16, 2020 | 68 | 2020 |
Astaxanthin is neuroprotective in an aged mouse model of Parkinson’s disease B Grimmig, L Daly, M Subbarayan, C Hudson, R Williamson, K Nash, ... Oncotarget 9 (12), 10388, 2018 | 56 | 2018 |
Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice AN Winter, MS Subbarayan, B Grimmig, JA Weesner, L Moss, M Peters, ... Journal of neuroinflammation 17, 1-14, 2020 | 42 | 2020 |
Astaxanthin supplementation modulates cognitive function and synaptic plasticity in young and aged mice B Grimmig, C Hudson, L Moss, M Peters, M Subbarayan, EJ Weeber, ... GeroScience 41, 77-87, 2019 | 24 | 2019 |
Concentration and proteolysis of CX3CL1 may regulate the microglial response to CX3CL1 D Finneran, Q Li, MS Subbarayan, A Joly‐Amado, S Kamath, DG Dengler, ... Glia 71 (2), 245-258, 2023 | 6 | 2023 |
Orthosteric- versus allosteric-dependent activation of the GABAA receptor requires numerically distinct subunit level rearrangements J Amin, MS Subbarayan Scientific Reports 7 (1), 7770, 2017 | 5 | 2017 |
Immune Modulation as a Therapeutic Target in an α-synuclein Model of Parkinson’s Disease MS Subbarayan University of South Florida, 2020 | | 2020 |
Role of T Cells in an Alpha-Synuclein Model of Parkinson's Disease MS Subbarayan, C Hudson, N Litsky, K Nash, PC Bickford CELL TRANSPLANTATION 28 (4), 486-487, 2019 | | 2019 |
Soluble CX3CL1 Rescues Cognitive Deficits in CX3CL1 Knock-Out Mice MS Subbarayan, AN Winter, B Grimmig, M Peters, E Weeber, KR Nash, ... CELL TRANSPLANTATION 27 (4), 715-715, 2018 | | 2018 |